Comparative in vitro study of SQ26,776
Open Access
- 1 February 1982
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 21 (2), 294-298
- https://doi.org/10.1128/aac.21.2.294
Abstract
A new monocyclic beta-lactam antibiotic, SQ26,776, was evaluated in vitro against clinical isolates, and its activity was compared with that of other cephalosporins, penicillins, and aminoglycosides. This compound was very active against the majority of the aerobic gram-negative bacilli tested, including 47 multiresistant strains. It had no activity against the gram-positive cocci. It also showed activity comparable to that of moxalactam, ceftazidime, ceftriaxone, thienamycin, and tobramycin. It was superior to mezlocillin. The in vitro activity suggests that SQ26,776 should prove useful in settings in which the most likely pathogens are gram-negative bacilli.This publication has 7 references indexed in Scilit:
- Sulfazecin and isosulfazecin, novel β-lactam antibiotics of bacterial originNature, 1981
- In vitro evaluation of Ro 13-9904Antimicrobial Agents and Chemotherapy, 1980
- In vitro evaluation of cefoperazoneAntimicrobial Agents and Chemotherapy, 1980
- In Vitro Activity of LY127935Antimicrobial Agents and Chemotherapy, 1979
- Hospital Isolates of Serratia marcescens Transferring Ampicillin, Carbenicillin, and Gentamicin Resistance to Other Gram-Negative Bacteria Including Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 1979
- Pseudomonas septicemia: Incidence, epidemiology, prevention and therapy in patients with advanced cancerEuropean Journal of Cancer (1965), 1973